Predictive Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update
PITTSBURGH, Nov. 14, 2023 (GLOBE NEWSWIRE) — Predictive Oncology (Nasdaq:POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the three and nine months ended September 30, 2023, and provided a corporate update. The company reported a net loss of $3.2 million on total net revenue of $0.7 million for the third quarter 2023.
Related news for (POAI)
- Predictive Oncology Inc. Announces Private Placements of $344 Million to Initiate a Digital Asset Treasury Strategy Focused on Aethir (ATH) Tokens
- 24/7 Market News Snapshot 29 September, 2025 – Predictive Oncology Inc. Common Stock (NASDAQ:POAI)
- Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp
- UPDATE – Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
- 24/7 Market News Snapshot 22 May, 2025 – Predictive Oncology Inc. Common Stock (NASDAQ:POAI)